Zobrazeno 1 - 10
of 107
pro vyhledávání: '"Lovastatin Acid"'
Autor:
Yingli ZHU, Hongshun GU, Jianjun ZHANG, Xiangshan WANG, Weican LIANG, Yingxin SHAO, Fan ZHAO, Yang LI, Limei ZHANG, Linyuan WANG
Publikováno v:
Shipin gongye ke-ji, Vol 44, Iss 14, Pp 290-295 (2023)
Objective: To establish a quantitative analysis of multi-components by single marker (QAMS) method for the determination of lovastatin and lovastatin acid for the quality control of Hongqu Fuling tablets. Methods: Lovastatin as a control, the RP-HPLC
Externí odkaz:
https://doaj.org/article/90295c7dcd70429dbe2cb6db63a6ce57
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
ACS Omega
ACS Omega, Vol 6, Iss 24, Pp 15804-15815 (2021)
ACS Omega, Vol 6, Iss 24, Pp 15804-15815 (2021)
Lovastatin is a standard therapy for dyslipidemia. Alternatively, some ethnomedicines, such as Coptidis preparation, have been used for the treatment of dyslipidemia. Statins and complementary and alternative medicines may possess individual mechanis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a25a8178a72ab5786b28f77e6d47a72
https://doi.org/10.1021/acsomega.1c01201
https://doi.org/10.1021/acsomega.1c01201
Autor:
Xin Lin, Hua Xiang, Lizhe Zhu, Zhenbang Li, Xinyu Li, Kun Xi, Yu Chen, Guoshun Luo, Hanlin Wei, Maoxu Xiao
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 5, Pp 1300-1314 (2021)
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica. B
HMG-CoA reductase (HMGCR) protein is usually upregulated after statin (HMGCR inhibitor) treatment, which inevitably diminishes its therapeutic efficacy, provoking the need for higher doses associated with adverse effects. The proteolysis targeting ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6312f6152cec18a667ff549cdcda8ade
http://www.sciencedirect.com/science/article/pii/S2211383520307772
http://www.sciencedirect.com/science/article/pii/S2211383520307772
Autor:
Reo Kawata, Tsuyoshi Yokoi
Publikováno v:
International Journal of Toxicology. 38:192-201
Because dogs are widely used in drug development as nonrodent experimental animals, using a dog model for drug-induced adverse reactions is considered to be relevant for an evaluation and investigation of a mechanism and a biomarker of clinical drug-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a5f8b9f56fc6d4cd8541f06d250547e
https://doi.org/10.1177/1091581819844793
https://doi.org/10.1177/1091581819844793
Autor:
Na Young Lim, Sun Hee Moon, Sun Young Baek, Hwan Seong Choi, Nam Sook Kim, Hyungil Kim, Ji Hyun Lee
Publikováno v:
Rapid Communications in Mass Spectrometry. 35
RATIONALE Recently, illegal dietary supplements containing unauthorized compounds have been seized and internationally publicized with a warning to avoid their consumption. This adulteration can be a serious threat to public health because of insuffi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3863ea99b5b3675658498ae74bffd21
https://doi.org/10.1002/rcm.8989
https://doi.org/10.1002/rcm.8989
Publikováno v:
Journal of Liquid Chromatography & Related Technologies. 41:668-675
An HPLC-MS/MS method was described for the quantitation of lovastatin and its main hydroxy acid metabolite lovastatin acid in human plasma. Lovastatin was detected in the positive ion mode, while L...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54e01d27337f826241723997338790dd
https://doi.org/10.1080/10826076.2018.1508473
https://doi.org/10.1080/10826076.2018.1508473
Publikováno v:
Current Pharmaceutical Biotechnology. 18:1141-1150
Background Drug-induced myopathy is a serious side effect that often requires removal of a medication from a drug regimen. For most drugs, the underlying mechanism of drug-induced myopathy remains unclear. Monocarboxylate transporters (MCTs) mediate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13a98c7a64a3d3893322a91a85e3ad5f
https://doi.org/10.2174/1389201019666180308091504
https://doi.org/10.2174/1389201019666180308091504
Publikováno v:
Pharmacogenomics. 18:65-75
Aim: This study examined whether gene polymorphisms (CYP3A4, ABCG2, SLCO1B1, NR1I2, PPARA and NFKB1) influenced the pharmacokinetics of lovastatin in Chinese healthy subjects. Patients & method: Plasma concentrations of lovastatin and lovastatin acid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::900d8c428d0f7e1169098f5fe9b623e5
https://doi.org/10.2217/pgs.16.31
https://doi.org/10.2217/pgs.16.31
Autor:
Ji-Ye Sun, Yu-Feng Shao, Wanhui Liu, Zhen-Wen Duan, Youxin Li, Chunjie Sha, Yan-Hong Liu, Jing Wang
Publikováno v:
Journal of Pharmaceutical Analysis
Journal of Pharmaceutical Analysis, Vol 5, Iss 6, Pp 383-388 (2015)
Journal of Pharmaceutical Analysis, Vol 5, Iss 6, Pp 383-388 (2015)
A stable HMG-CoA reductase (HMGR) reaction in vitro was developed by a sensitive, selective and precise liquid chromatography–tandem mass spectrometry (LC–MS/MS) method. The optimized enzyme reaction condition contained 1.5 μg of HMGR, 20 nM of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4618a76704f2631d34155205a4e5c12f
http://europepmc.org/articles/PMC5762244
http://europepmc.org/articles/PMC5762244